Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura

Presse Medicale

Volumn 41, Issue 3 PART 2, 2012, Pages

  Mannucci, Pier Mannuccio ^a   Franchini, Massimo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ANTIBODY DETECTION; DIAGNOSTIC VALUE; DISEASE DURATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN CLEAVAGE; RECURRENCE RISK; RELAPSE; REMISSION; RISK ASSESSMENT; SHORT SURVEY; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84857440816     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.10.025     Document Type: Short Survey

References (50)

1. Tsai H.M. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003, 14:1072-1081.
2. Sadler J.E., Moake J.L., Miyata T., George J.N. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2004, 407-423.
3. Mannucci P.M., Lavoretano S., Peyvandi S. The thrombotic microangiopathies. Blood Transfus 2005, 3:120-135.
4. George J.N. Thrombotic thrombocytopenic puprura. N Engl J Med 2006, 354:1927-1935.
5. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924, 24:21-24.
6. Amorosi E.L., Ultmann J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966, 45:139-159.
7. Lämmle B., Kremer Hovinga A., Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005, 3:1663-1675.
8. Moake J.L., Rudy C.K., Troll J.H., et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982, 307:1432-1435.
9. Furlan M., Robles R., Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87:4223-4234.
10. Tsai H.-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996, 87:4235-4244.
11. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsingrelapsing thrombotic thrombocytopenic purpura. Blood 1997, 89:3097-3103.
12. Furlan M., Robles R., Galbusera M., et al. Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339:1578-1584.
13. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594.
14. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98:1662-1666.
15. Gerritsen H.E., Robles R., Lammle B., Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001, 98:1654-1661.
16. Soejima K., Mimura N., Hirashima M., et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001, 130:475-480.
17. Zheng X., Chung D., Takayama T.K., et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001, 276:41059-41063.
18. Tsai H.-M. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007, 21:609-632.
19. Tsai H.M. Molecular mechanisms in thrombotic thrombovytopenic purpura. Semin Thromb Hemost 2004, 30:549-556.
20. Schulman I., Pierce M., Lukens A., Currimbhoy Z. Studies on thrombopoeisis. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960, 16:943-957.
21. Upshaw J.D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978, 298:1350-1352.
22. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413:488-494.
23. Klaus C., Plaimauer B., Studt J.D., et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004, 103:4514-4519.
24. Scheiflinger F., Knöbl P., Trattner B., et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003, 102:3241-3243.
25. Rieger M., Mannucci P.M., Hovinga J.A., et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005, 106:1262-1267.
26. van der Plas R.M., Schiphorst M.E., Huizinga E.G., et al. Von Willebrand factor proteolysis is deficient in classic but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999, 93:3798-3802.
27. Tsai H.M. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006, 57:419-436.
28. Furlan M., Lammle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2002, 28:167-172.
29. Veyradier A., Girma J.P. Assays of ADAMTS-13 activity. Semin Hematol 2004, 41:41-47.
30. Miyata T., Kokame K., Banno F. Measurement of ADAMTS13 activity and inhibitors. Curr Opin Hematol 2005, 12:384-389.
31. Kokame K., Nobe Y., Kokubo Y., et al. FRETS-VWF73, a fluorogenic substrate for ADAMTS13 assay. Br J Haemost 2005, 129:93-100.
32. Groot E., Hulstein J.J., Rison C.N., de Groot P.G., Fijnheer R. FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Throm Haemost 2006, 4:698-699.
33. Feys H.B., Canciani M.T., Peyvandi F., Deckmyn H., Vanhoorelbeke K., Mannucci P.M. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007, 138:534-540.
34. Scheiflinger F., Knobl P., Trattner B., et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003, 102:3241-3243.
35. Bianchi V., Robles R., Alberio L., Furlan M., Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002, 100:710-713.
36. Franchini M., Mannucci P.M. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus 2008, 6:127-135.
37. Veyradier A., Obert B., Houllier A., Meyer D., Girma J.P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001, 98:1765-1772.
38. Peyvandi F., Ferrari S., Lavoretano S., Canciani M.T., Mannucci P.M. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004, 127:433-439.
39. Mori Y., Wada H., Gabazza E.C., et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002, 42:572-580.
40. Vesely S.K., George J.N., Lammle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102:60-68.
41. Coppo P., Bengoufa D., Veyradier A., et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004, 83:233-244.
42. Zheng X.L., Kaufman R.M., Goodnough L.T., Sadler J.E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004, 103:4043-4049.
43. Mannucci P.M., Peyvandi F. TTP and ADAMTS13: when is testing appropriate?. Hematology (Am Soc Hematol Educ Program) 2007, 121-126.
44. Raife T., Atkinson B., Montgomery R., Vesely S., Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004, 44:146-150.
45. Coppo P., Wolf M., Veyradier A., et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2005, 132:66-74.
46. Böhm M., Betz C., Miesbach W., et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005, 129:644-652.
47. Ferrari S., Scheiflinger F., Rieger M., et al. French clinical and biological network on adult thrombotic microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007, 109:2815-2822.
48. Peyvandi F., Lavoretano S., Palla R., et al. ADAMTS13 and anti-adamts13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008, 93:232-239.
49. Jin M., Casper C., Spero R., Cataland S.R., et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008, 141:651-658.
50. Kremer Hovinga J.A., Vesely S.K., Terrel D.R., Lammle B., George J.N. Survival and relapse in patients with thrombotic thromocytopenic purpura. Blood 2010, 115:1500-1511.